{"altmetric_id":3303628,"counts":{"readers":{"mendeley":25,"citeulike":0,"connotea":0},"total":{"posts_count":1},"wikipedia":{"unique_users_count":1,"unique_users":["en:1411989"],"posts_count":1}},"citation":{"altmetric_jid":"4f6fa6223cf058f610007be5","authors":["Catherine Skagen","Michael Einstein","Michael R. Lucey","Adnan Said"],"doi":"10.1097\/mcg.0b013e318188947c","endpage":"685","first_seen_on":"2015-02-04T08:18:22+00:00","issns":["0192-0790"],"issue":"7","journal":"Journal of Clinical Gastroenterology","last_mentioned_on":1236609056,"links":["http:\/\/dx.doi.org\/10.1097\/MCG.0b013e318188947c","http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/19238094"],"pubdate":"2009-08-01T00:00:00+00:00","publisher_subjects":[{"name":"Clinical Sciences","scheme":"era"}],"scopus_subjects":["Medicine","Health Sciences"],"startpage":"680","subjects":["gastroenterology"],"title":"Combination treatment with octreotide, midodrine, and albumin improves survival in patients with type 1 and type 2 hepatorenal syndrome.","type":"article","volume":"43","mendeley_url":"http:\/\/www.mendeley.com\/research\/combination-treatment-octreotide-midodrine-albumin-improves-survival-patients-type-1-type-2-hepatore-6"},"altmetric_score":{"score":3,"score_history":{"1y":0,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":3},"context_for_score":{"all":{"total_number_of_other_articles":3626012,"mean":4.9497445252532,"rank":817909,"this_scored_higher_than_pct":63,"this_scored_higher_than":2285108,"rank_type":"exact","sample_size":3626012,"percentile":63},"similar_age_3m":{"total_number_of_other_articles":93524,"mean":8.0028659687991,"rank":24145,"this_scored_higher_than_pct":73,"this_scored_higher_than":68294,"rank_type":"exact","sample_size":93524,"percentile":73},"this_journal":{"total_number_of_other_articles":1087,"mean":2.3085064456722,"rank":137,"this_scored_higher_than_pct":75,"this_scored_higher_than":817,"rank_type":"exact","sample_size":1087,"percentile":75},"similar_age_this_journal_3m":{"total_number_of_other_articles":36,"mean":2.1685714285714,"rank":2,"this_scored_higher_than_pct":91,"this_scored_higher_than":33,"rank_type":"exact","sample_size":36,"percentile":91}}},"demographics":{"users":{"mendeley":{"by_status":{"Professor > Associate Professor":1,"Researcher":3,"Student  > Doctoral Student":1,"Student  > Ph. D. Student":1,"Student  > Postgraduate":6,"Other":9,"Student  > Master":3,"Professor":1},"by_discipline":{"Medicine and Dentistry":21,"Agricultural and Biological Sciences":4}}},"geo":{"mendeley":{"US":2,"AU":1,"DE":1}}},"posts":{"wikipedia":[{"title":"Octreotide","url":"http:\/\/en.wikipedia.org\/?diff=prev&oldid=276038858#altmetric_citation_2","license":"public","citation_ids":[3303628],"posted_on":"2009-03-09T14:30:56+00:00","summary":"Octreotide can also be labelled with a variety of radionuclides, such as yttrium-90 or lutetium-177, to enable peptide receptor radionuclide therapy (PRRT) for the treatment of unresectable neuroendocrine tumours.","page_url":"http:\/\/en.wikipedia.org\/?curid=1411989","wiki_lang":"en","author":{"name":"Jalaly","url":"http:\/\/en.wikipedia.org\/wiki\/User:Jalaly"}}]}}